205 related articles for article (PubMed ID: 18602242)
21. When Does the Incremental Risk Format Aid Informed Medical Decisions? The Role of Learning, Feedback, and Number of Treatment Options.
Tiede KE; Ripke F; Degen N; Gaissmaier W
Med Decis Making; 2020 Feb; 40(2):212-221. PubMed ID: 32036764
[No Abstract] [Full Text] [Related]
22. Patient reluctance toward tamoxifen use for breast cancer primary prevention.
Port ER; Montgomery LL; Heerdt AS; Borgen PI
Ann Surg Oncol; 2001 Aug; 8(7):580-5. PubMed ID: 11508619
[TBL] [Abstract][Full Text] [Related]
23. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
26. The influence of graphic display format on the interpretations of quantitative risk information among adults with lower education and literacy: a randomized experimental study.
McCaffery KJ; Dixon A; Hayen A; Jansen J; Smith S; Simpson JM
Med Decis Making; 2012; 32(4):532-44. PubMed ID: 22074912
[TBL] [Abstract][Full Text] [Related]
27. Alternate methods of framing information about medication side effects: incremental risk versus total risk of occurrence.
Zikmund-Fisher BJ; Fagerlin A; Roberts TR; Derry HA; Ubel PA
J Health Commun; 2008 Mar; 13(2):107-24. PubMed ID: 18300064
[TBL] [Abstract][Full Text] [Related]
28. Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
Sherman KA; Kilby CJ; Shaw LK; Winch C; Kirk J; Tucker K; Elder E
Breast; 2017 Dec; 36():79-85. PubMed ID: 29031121
[TBL] [Abstract][Full Text] [Related]
29. Informing patients: the influence of numeracy, framing, and format of side effect information on risk perceptions.
Peters E; Hart PS; Fraenkel L
Med Decis Making; 2011; 31(3):432-6. PubMed ID: 21191122
[TBL] [Abstract][Full Text] [Related]
30. Evaluating a combined (frequency and percentage) risk expression to communicate information on medicine side effects to patients.
Knapp P; Gardner P; McMillan B; Raynor DK; Woolf E
Int J Pharm Pract; 2013 Aug; 21(4):226-32. PubMed ID: 23419135
[TBL] [Abstract][Full Text] [Related]
31. The benefits and costs of tamoxifen for breast cancer prevention.
Eckermann SD; Martin AJ; Stockler MR; Simes RJ
Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
[TBL] [Abstract][Full Text] [Related]
32. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
Gail MH; Costantino JP; Bryant J; Croyle R; Freedman L; Helzlsouer K; Vogel V
J Natl Cancer Inst; 1999 Nov; 91(21):1829-46. PubMed ID: 10547390
[TBL] [Abstract][Full Text] [Related]
33. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
34. Using animated computer-generated text and graphics to depict the risks and benefits of medical treatment.
Tait AR; Voepel-Lewis T; Brennan-Martinez C; McGonegal M; Levine R
Am J Med; 2012 Nov; 125(11):1103-10. PubMed ID: 22939094
[TBL] [Abstract][Full Text] [Related]
35. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen for prevention of breast cancer.
Cersosimo RJ
Ann Pharmacother; 2003 Feb; 37(2):268-73. PubMed ID: 12549959
[TBL] [Abstract][Full Text] [Related]
37. Perceived risk of tamoxifen side effects: a study of the use of absolute frequencies or frequency bands, with or without verbal descriptors.
Knapp P; Gardner PH; Raynor DK; Woolf E; McMillan B
Patient Educ Couns; 2010 May; 79(2):267-71. PubMed ID: 19896321
[TBL] [Abstract][Full Text] [Related]
38. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
Paterniti DA; Melnikow J; Nuovo J; Henderson S; DeGregorio M; Kuppermann M; Nease R
Ethn Dis; 2005; 15(3):365-72. PubMed ID: 16108294
[TBL] [Abstract][Full Text] [Related]
39. Information needs and preferences of low and high literacy consumers for decisions about colorectal cancer screening: utilizing a linguistic model.
Smith SK; Trevena L; Nutbeam D; Barratt A; McCaffery KJ
Health Expect; 2008 Jun; 11(2):123-36. PubMed ID: 18494957
[TBL] [Abstract][Full Text] [Related]
40. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.
Cook LS; Weiss NS; Schwartz SM; White E; McKnight B; Moore DE; Daling JR
J Natl Cancer Inst; 1995 Sep; 87(18):1359-64. PubMed ID: 7658496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
